John Hilterman/LinkedIn
Nov 5, 2025, 05:09
Rethinking Anticoagulants in Hospice
John Hilterman, Business Development Manager at Wise Hospice Option, posted on LinkedIn:
”Safer care starts with clearer insight.
For many hospice patients, the goal shifts from prevention to comfort – and that means re-evaluating medications like anticoagulants and antiplatelets.
Our latest Hospice Pharmacist’s Brief outlines when deprescribing is clinically appropriate, how to manage risk, and ways to align therapy with quality-of-life goals.”
Read more here.
Keep up with Hemostasis Today.
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases
-
Feb 24, 2026, 15:30Aswin K Mohan: Practical Tips for Preparing Before, During, and After Blood Donation
-
Feb 24, 2026, 15:24Stéphanie Forté: The Hidden Burden of Stroke in Adults Living with Sickle Cell Disease
-
Feb 24, 2026, 15:13Tagreed Alkaltham: Equity in Emergency Care Through a Blood Bank Lens
-
Feb 24, 2026, 14:57Joseph Raffaele: Can Improving Mitochondrial Quality in Immune Cells Alter Immune Aging Markers?